News

Key to herbicide resistance
Enlarge image

ResearchUK

Key to herbicide resistance

26.03.2013 - British researchers have found that one single protein seems to control resistance against multiple herbicides of cereal crops weeds.

Multiple-herbicide resistance (MHR) in black-grass and annual rye-grass is a global threat for agriculture, leading to loss of chemical weed control in cereal crops. Until now, it was only poorly understood why MHR is associated with an enhanced ability to detoxify xenobiotics. Assuming an analogy with multiple drug resistance, which occurs in human tumours, researchers from York University and Syngenta now report they have found a possible explanation.

When they searched in black-grass and annual rye-grass for a plant homologue to the MDR causing phi glutathione S transferase (GSTP1) they found an enzyme that also showed both detoxification and signalling. When expressed in Arabidopsis thaliana, the protein termed GSTF1 led to multiple herbicide resistance in the model organism and showed a similar secondary metabolism pattern as the weeds. Those were not associated with a differential gene expression pattern but directly caused by GSTF1.

When they applied the GSTP1 blocker 4-chloro-7-nitro-benzoxadiazole to the weeds, the MHR masterswitch was blocked. They conclude that overexpression of GSTF1 orchestrates multi-herbicide resistance in grass weeds and that targeting the protein is a promising approach to regain weed control in cereal crops.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/masterswitch-for-herbicide-resistance.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR29.9%
  • ADDEX3.44 CHF5.8%
  • HBM86.00 CHF3.7%

FLOP

  • PAION2.19 EUR-32.6%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-26.3%

TOP

  • SANTHERA82.00 CHF2269.9%
  • CO.DON2.82 EUR209.9%
  • PAION2.19 EUR154.7%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014